Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

SAN DIEGO, January 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $446.4 million specializing in mRNA therapeutics and vaccines ...